What were Kilitch Drugs (India) Ltd's latest quarterly results?
Kilitch Drugs (India) Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -23.2%
- Revenue Growth YoY: -4.2%
- Operating Margin: 11.4%
Kilitch Drugs (India) Ltd: Stock Analysis & Fundamentals
Updated this weekKilitch Drugs (India) Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 18.6. ROE: 12.6%. This stock is not currently in the Nifty 500 momentum outperformers list.
What's Happening
📊Debt increased 71% YoY — leverage rising
👔Promoter stake down 5.5% this quarter
Key Numbers
Current Price
₹139
Market Cap
486 Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Kilitch Drugs (India) Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Kilitch Drugs (India) Ltd's current PE ratio?
Kilitch Drugs (India) Ltd's current PE ratio is 18.6x.
- Current PE: 18.6x
- Market Cap: 486 Cr
What is Kilitch Drugs (India) Ltd's price-to-book ratio?
Kilitch Drugs (India) Ltd's price-to-book ratio is 1.8x.
- Price-to-Book (P/B): 1.8x
- Book Value per Share: ₹76
- Current Price: ₹139
Is Kilitch Drugs (India) Ltd a fundamentally strong company?
Kilitch Drugs (India) Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 16.0%
Is Kilitch Drugs (India) Ltd debt free?
Kilitch Drugs (India) Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹84 Cr
What is Kilitch Drugs (India) Ltd's return on equity (ROE) and ROCE?
Kilitch Drugs (India) Ltd's return ratios over recent years
- FY2023: ROCE 10.0%
- FY2024: ROCE 13.0%
- FY2025: ROCE 16.0%
Is Kilitch Drugs (India) Ltd's cash flow positive?
Kilitch Drugs (India) Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹18 Cr
- Free Cash Flow (FCF): ₹-22 Cr
- CFO/PAT Ratio: 72% (adequate)
What is Kilitch Drugs (India) Ltd's dividend yield?
Kilitch Drugs (India) Ltd currently does not pay a significant dividend (yield 0.00%).
- Dividend Yield: 0.00%
- Current Price: ₹139
Who holds Kilitch Drugs (India) Ltd shares — promoters, FII, DII?
Kilitch Drugs (India) Ltd's shareholding pattern (Mar 2026)
- Promoters: 63.8%
- Public: 36.2%
Is promoter holding increasing or decreasing in Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 63.8% (Mar 2026)
- Previous Quarter: 63.8% (Dec 2025)
- Change: 0.00% (stable)
Is Kilitch Drugs (India) Ltd a new momentum entry or an established outperformer?
Kilitch Drugs (India) Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Kilitch Drugs (India) Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Kilitch Drugs (India) Ltd may be worth studying
- Cash flow is positive — CFO ₹18 Cr
What is the investment thesis for Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd investment thesis summary:
What is the future outlook for Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.